全文获取类型
收费全文 | 453篇 |
免费 | 35篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 45篇 |
妇产科学 | 14篇 |
基础医学 | 28篇 |
口腔科学 | 1篇 |
临床医学 | 18篇 |
内科学 | 29篇 |
皮肤病学 | 5篇 |
神经病学 | 6篇 |
特种医学 | 2篇 |
外科学 | 221篇 |
预防医学 | 9篇 |
药学 | 21篇 |
肿瘤学 | 88篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 4篇 |
2020年 | 4篇 |
2019年 | 3篇 |
2018年 | 9篇 |
2017年 | 10篇 |
2016年 | 10篇 |
2015年 | 13篇 |
2014年 | 14篇 |
2013年 | 15篇 |
2012年 | 25篇 |
2011年 | 27篇 |
2010年 | 16篇 |
2009年 | 20篇 |
2008年 | 23篇 |
2007年 | 28篇 |
2006年 | 31篇 |
2005年 | 15篇 |
2004年 | 32篇 |
2003年 | 28篇 |
2002年 | 21篇 |
2001年 | 36篇 |
2000年 | 19篇 |
1999年 | 17篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 4篇 |
1995年 | 7篇 |
1994年 | 1篇 |
1993年 | 8篇 |
1992年 | 15篇 |
1991年 | 12篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 4篇 |
排序方式: 共有488条查询结果,搜索用时 15 毫秒
1.
Idris Olasunmbo Ola Kirsi Talala Teuvo Tammela Kimmo Taari Teemu Murtola Paula Kujala Jani Raitanen Anssi Auvinen 《International journal of cancer. Journal international du cancer》2023,152(4):672-678
Prostate-specific antigen (PSA)-based screening for prostate cancer (PCa) can reduce PCa mortality, but also involves overdetection of low-risk disease with potential adverse effects. We evaluated PCa incidence among men with PSA below 3 ng/mL and no PCa diagnosis at the first screening round of the Finnish Randomized Study of Screening for PCa. Follow-up started at the first screening attendance and ended at PCa diagnosis, emigration, death or the common closing date (December 2016), whichever came first. Cox regression analysis was used to estimate hazard ratios and their confidence intervals (CI). Among men with PSA <3 ng/mL, cumulative PCa incidence was 9.1% after 17.6 years median follow-up. Cumulative incidence was 3.6% among men with baseline PSA 0 to 0.99 ng/mL, 11.5% in those with PSA 1.0 to 1.99 ng/mL and 25.7% among men with PSA 2 to 2.99 ng/mL (hazard ratio 9.0, 95% CI: 7.9-10.2 for the latter). The differences by PSA level were most striking for low-risk disease based on Gleason score and EAU risk group. PSA values <1 ng/mL indicate a very low 20-year risk, while at PSA 2 to 2.99 ng/mL risks are materially higher, with 4- to 5-fold risk for aggressive disease. Using risk-stratification and appropriate rescreening intervals will reduce screening intensity and overdetection. Using cumulative incidence of clinically significant PCa (csPCa) as the criterion, rescreening intervals could range from approximately 3 years for men with initial PSA 2 to 2.99 ng/mL, 6 years for men with PSA 1 to 1.99 ng/mL to 10 years for men with PSA <1 ng/mL. 相似文献
2.
3.
4.
5.
Pakkanen S Kujala PM Ha N Matikainen MP Schleutker J Tammela TL 《BJU international》2012,109(4):557-563
Study Type – Aetiology (cohort) Level of Evidence 2b
OBJECTIVE
? To describe clinical and histopathological characteristics of Finnish familial prostate cancer (PCa) through a detailed analysis of cases in families.PATIENTS AND METHODS
? In total, 202 Finnish families with 617 histopathologically confirmed PCa cases of confirmed genealogy were collected. ? Complete clinical data, including age and prostate‐specific antigen (PSA) at diagnosis, stage, grade and primary treatment, were gathered. The mean (range) number of affected men per family was 3 (2–8). ? All the available diagnostic biopsy samples (n= 323) were collected and regraded by the same uropathologist. ? A population‐based cohort of 3011 hospital district Pirkanmaa PCa patients was used as a control group.RESULTS
? The mean (range) year of diagnosis of PCa was 1993 (1962–2006) and the mean (range) age at diagnosis was 68 (43–98 years). ? The median (range) primary PSA level was 12.0 (0.8–11 000) ng/mL. After regrading, the Gleason score was ≤6 in 38%, 7 in 37% and ≥8 in 25% of men. ? The subset of familial PCa men diagnosed after 1995 had higher PSA levels (P= 9.9 × 10?6) and an earlier age of onset (P= 1.7 × 10?6) than men in the control group, although there were no differences in cancer‐specific survival.CONCLUSIONS
? We observed an earlier age of onset and higher PSA in familial PCa. ? However, differences between sporadic and familial or hereditary PCa cannot be truly solved until genetic testing of high‐risk genes in addition to family history is used to define PCa families. ? We also emphasize that, when histological samples are collected over a longer study period, reanalysis of the samples by the same experienced uropathologist should be considered. What’s known on the subject? and What does the study add? Previous hospital‐ or population‐based cross‐sectional studies comparing the clinical and histopathological features of hereditary, familial and sporadic PCa either reported weak trends or no differences in features measured except the age of onset. In present study we observed higher PSA and earlier age of onset in the subset of 257 familial PCa menin Finnish PCa families. 相似文献6.
Nora Pashayan Paul DP Pharoah Johanna Schleutker Kirsi Talala Teuvo LJ Tammela Liisa M??tt?nen Patricia Harrington Jonathan Tyrer Rosalind Eeles Stephen W Duffy Anssi Auvinen 《British journal of cancer》2015,113(7):1086-1093
Background:
We derived estimates of overdiagnosis by polygenic risk groups and examined whether polygenic risk-stratified screening for prostate cancer reduces overdiagnosis.Methods:
We calculated the polygenic risk score based on genotypes of 66 known prostate cancer loci for 4967 men from the Finnish section of the European Randomised Study of Screening for Prostate Cancer. We stratified the 72 072 men in the trial into those with polygenic risk below and above the median. Using a maximum likelihood method based on interval cancers, we estimated the mean sojourn time (MST) and episode sensitivity. For each polygenic risk group, we estimated the proportion of screen-detected cancers that are likely to be overdiagnosed from the difference between the observed and expected number of screen-detected cancers.Results:
Of the prostate cancers, 74% occurred among men with polygenic risk above population median. The sensitivity was 0.55 (95% confidence interval (CI) 0.45–0.65) and MST 6.3 (95% CI 4.2–8.3) years. The overall overdiagnosis was 42% (95% CI 37–52) of the screen-detected cancers, with 58% (95% CI 54–65) in men with the lower and 37% (95% CI 31–47) in those with higher polygenic risk.Conclusion:
Targeting screening to men at higher polygenic risk could reduce the proportion of cancers overdiagnosed. 相似文献7.
Lasse Saarimäki Teuvo L. Tammela Liisa Määttänen Kimmo Taari Paula M. Kujala Jani Raitanen Anssi Auvinen 《International journal of cancer. Journal international du cancer》2015,136(9):2172-2177
Family history (FH) is one of the few known risk factors for prostate cancer (PC). There is also new evidence about mortality reduction in screening of PC with prostate‐specific antigen (PSA). Therefore, we conducted a prospective study in the Finnish Prostate Cancer Screening Trial to evaluate the impact of FH on outcomes of PC screening. Of the 80,144 men enrolled, 31,866 men were randomized to the screening arm and were invited for screening with PSA test (cut‐off 4 ng/ml) every 4 years. At the time of each invitation, FH of PC (FH) was assessed through a questionnaire. The analysis covered a follow‐up of 12 years from randomization for all men with data on FH. Of the 23,702 (74.3%) invited men attending screening, 22,756 (96.0%) provided information of their FH. Altogether 1,723 (7.3%) men reported at least one first‐degree relative diagnosed with PC and of them 235 (13.6%) were diagnosed with PC. Men with a first‐degree FH had increased risk for PC (risk ratio (RR) 1.31, p < 0.001) and the risk was especially elevated for interval cancer (RR 1.65, 95% CI 1.27–2.15). Risk for low‐grade (Gleason 2–6) tumors was increased (RR 1.46, 95% CI 1.15–1.69), but it was decreased for Gleason 8–10 tumors (RR 0.48, 95% CI 0.25–0.95). PSA test performance (sensitivity and specificity) was slightly inferior for FH positives. No difference in PC mortality was observed in terms of FH. Our findings provide no support for selective PSA screening targeting men with FH of PC. 相似文献
8.
9.
Fine‐mapping the 2q37 and 17q11.2‐q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer 下载免费PDF全文
10.
The biology of vascular endothelial growth factors 总被引:30,自引:0,他引:30
The discovery of the vascular endothelial growth factor (VEGF) family members VEGF, VEGF-B, placental growth factor (PlGF), VEGF-C and VEGF-D and their receptors VEGFR-1, -2 and -3 has provided tools for studying the vascular system in development as well as in diseases ranging from ischemic heart disease to cancer. VEGF has been established as the prime angiogenic molecule during development, adult physiology and pathology. PlGF may primarily mediate arteriogenesis, the formation of collateral arteries from preexisting arterioles, with potential future therapeutic use in for example occlusive atherosclerotic disease. VEGF-C and VEGF-D are primarily lymphangiogenic factors, but they can also induce angiogenesis in some conditions. While many studies have addressed the role of angiogenesis and the blood vasculature in human physiology, the lymphatic vascular system has until recently attracted very little attention. In this review, we will discuss recent advances in angiogenesis research and provide an overview of the molecular players involved in lymphangiogenesis. 相似文献